The oncogenic role of IGF2BP3 in tumorigenesis and tumor progression has been reported by previous studies, confirming our observations of IGF2BP3’s correlation with a poor prognosis in mCRPC patients [50]. This evidence concerns the gene IGF2BP3 and neoplasm.